Form 4: Enliven Therapeutics Director Gupta Sells Shares in Open Market Transactions

Director Rishi Gupta reports selling shares of Enliven Therapeutics indirectly through OrbiMed funds in transactions totaling over $29 million.

Summary

• Rishi Gupta, a director of Enliven Therapeutics, reported transactions involving the company's common stock on May 16, 2024.
• Gupta indirectly disposed of 33,300 shares at a price of $22.14 per share.
• Additionally, Gupta indirectly disposed of 1,000,000 shares at the same price of $22.14 per share.
• These shares were held by OrbiMed Genesis Master Fund, L.P. and OrbiMed Private Investments VII, LP, for which OrbiMed Advisors LLC acts as the managing member.
• Following these transactions, Gupta indirectly holds 254,814 shares through OrbiMed Genesis Master Fund, L.P. and 7,663,349 shares through OrbiMed Private Investments VII, LP.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative due to the sale of shares by a director, which could be perceived as a lack of confidence in the company's future prospects, although the sales were indirect.

Negatives

• A director indirectly sold a significant number of shares, which could be interpreted negatively by the market.

Risks

• The sale of a large number of shares by a director could create downward pressure on the stock price.
• Market perception of insider selling could negatively impact investor confidence.

Industry Context

Sales by directors are a common occurrence, but the market often scrutinizes the timing and size of these transactions for insights into the company's prospects.

Stakeholder Impact

• Shareholders may react to the news of the director's share sales.
• The stock price could be affected by the transactions.

Key Dates